Stmnt re Share Price Movement

RNS Number : 6397K
Advanced Oncotherapy PLC
20 April 2015
 



 

20 April 2015

Advanced Oncotherapy plc

("AVO" or the "Company")

 

Share Price Movement

 

 

The board of Advanced Oncotherapy (AIM: AVO) notes the sharp rise in the Company's share price last week. It confirms that it is not aware of any fundamental reasons for this and that there has not been any change in the Company's activities since the last update on 2 April 2015. However, the Company is currently considering an equity issue to complete its first proton therapy LIGHT machine which is due to be fully assembled and tested by the end of 2016 and to accelerate the development of further machines in its pipeline.

 

 

For further information, please contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

 

 

 

Westhouse Securities (Nomad & Joint Broker)

 

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

 

 

Beaufort Securities (Joint Broker)

 

Saif Janjua / Jon Levinson

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMEAXLXFSSSEFF
UK 100

Latest directors dealings